Literature DB >> 22945591

Uric acid as a danger signal in gout and its comorbidities.

Kenneth L Rock1, Hiroshi Kataoka, Jiann-Jyh Lai.   

Abstract

Uric acid is a waste product of purine catabolism. This molecule comes to clinical attention when it nucleates to form crystals of monosodium urate (MSU) in joints or other tissues, and thereby causes the inflammatory disease of gout. Patients with gout frequently suffer from a number of comorbid conditions including hypertension, diabetes mellitus and cardiovascular disease. Why MSU crystals trigger inflammation and are associated with comorbidities of gout has been unclear, but recent studies provide new insights into these issues. Rather than simply being a waste product, uric acid could serve a pathophysiological role as a local alarm signal that alerts the immune system to cell injury and helps to trigger both innate and adaptive immune responses. The inflammatory component of these immune responses is caused when urate crystals trigger both inflammasome-dependent and independent pathways to generate the proinflammatory cytokine IL-1. The resulting bioactive IL-1 stimulates the inflammation of gout and might contribute to the development of other comorbidities. Surprisingly, the same mechanisms underlie the inflammatory response to a number of irritant particles, many of which also cause disease. These new insights help to explain the pathogenesis of gout and point to potential new therapeutic targets for this and other sterile inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22945591      PMCID: PMC3648987          DOI: 10.1038/nrrheum.2012.143

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  130 in total

1.  Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3 inflammasome in mice.

Authors:  Sharmal Narayan; Borbala Pazar; Borbola Pazar; Hang-Korng Ea; Laeticia Kolly; Nathaliane Bagnoud; Véronique Chobaz; Frédéric Lioté; Thomas Vogl; Dirk Holzinger; Alexander Kai-Lik So; Nathalie Busso
Journal:  Arthritis Rheum       Date:  2011-02

Review 2.  Innate and adaptive immune responses to cell death.

Authors:  Kenneth L Rock; Jiann-Jyh Lai; Hajime Kono
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

Review 3.  Sensing damage by the NLRP3 inflammasome.

Authors:  Jaklien C Leemans; Suzanne L Cassel; Fayyaz S Sutterwala
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

4.  Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro.

Authors:  Borbála Pazár; Hang-Korng Ea; Sharmal Narayan; Laeticia Kolly; Nathalie Bagnoud; Véronique Chobaz; Thierry Roger; Frédéric Lioté; Alexander So; Nathalie Busso
Journal:  J Immunol       Date:  2011-01-14       Impact factor: 5.422

Review 5.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Authors:  Charles A Dinarello
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

6.  Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing.

Authors:  U Schönbeck; F Mach; P Libby
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

7.  Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry.

Authors:  M S Horwitz; L M Bradley; J Harbertson; T Krahl; J Lee; N Sarvetnick
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

Review 8.  Inflammasomes: current understanding and open questions.

Authors:  Franz Bauernfeind; Andrea Ablasser; Eva Bartok; Sarah Kim; Jonathan Schmid-Burgk; Taner Cavlar; Veit Hornung
Journal:  Cell Mol Life Sci       Date:  2010-10-31       Impact factor: 9.207

9.  The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance.

Authors:  Bolormaa Vandanmagsar; Yun-Hee Youm; Anthony Ravussin; Jose E Galgani; Krisztian Stadler; Randall L Mynatt; Eric Ravussin; Jacqueline M Stephens; Vishwa Deep Dixit
Journal:  Nat Med       Date:  2011-01-09       Impact factor: 53.440

10.  Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction.

Authors:  C Kurts; J F Miller; R M Subramaniam; F R Carbone; W R Heath
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  117 in total

Review 1.  Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association.

Authors:  Ibrahim Mortada
Journal:  Curr Hypertens Rep       Date:  2017-09       Impact factor: 5.369

2.  Psoriasis, psoriatic arthritis and risk of gout in US men and women.

Authors:  Joseph F Merola; Shaowei Wu; Jiali Han; Hyon K Choi; Abrar A Qureshi
Journal:  Ann Rheum Dis       Date:  2014-03-20       Impact factor: 19.103

3.  Urate crystals directly activate the T-cell receptor complex and induce T-cell proliferation.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Georgia Antoniadi; Ioannis Tsialtas; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Biomed Rep       Date:  2017-08-04

4.  Expression of PYCARD gene transcript variant mRNA in peripheral blood mononuclear cells of primary gout patients with different Chinese medicine syndromes.

Authors:  Wan-Tai Dang; Wen-Guang Xie; Jing-Guo Zhou
Journal:  Chin J Integr Med       Date:  2017-10-30       Impact factor: 1.978

Review 5.  Inflammasomes and metabolic disorders: old genes in modern diseases.

Authors:  Gregory R Robbins; Haitao Wen; Jenny P-Y Ting
Journal:  Mol Cell       Date:  2014-04-24       Impact factor: 17.970

6.  Blockade of ERK1/2 by U0126 alleviates uric acid-induced EMT and tubular cell injury in rats with hyperuricemic nephropathy.

Authors:  Min Tao; Yingfeng Shi; Lunxian Tang; Yi Wang; Lu Fang; Wei Jiang; Tao Lin; Andong Qiu; Shougang Zhuang; Na Liu
Journal:  Am J Physiol Renal Physiol       Date:  2019-01-16

Review 7.  Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.

Authors:  Samir G Mallat; Sahar Al Kattar; Bassem Y Tanios; Abdo Jurjus
Journal:  Curr Hypertens Rep       Date:  2016-10       Impact factor: 5.369

8.  Angiogenic and innate immune responses triggered by PRP in tendon cells are not modified by hyperuricemia.

Authors:  Isabel Andia; Eva Rubio-Azpeitia
Journal:  Muscles Ligaments Tendons J       Date:  2014-11-17

9.  Hyperuricemia has an adverse impact on the prognosis of patients with osteosarcoma.

Authors:  Shangzeng Wang; Xiaoya Liu; Zike He; Xinfeng Chen; Wei Li
Journal:  Tumour Biol       Date:  2015-08-18

Review 10.  The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis?

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.